Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Fuji Pharma Co., Ltd. (FUP.F)

Compare
7.65
-0.20
(-2.55%)
At close: April 4 at 8:13:02 AM GMT+2
Loading Chart for FUP.F
  • Previous Close 7.85
  • Open 7.65
  • Bid --
  • Ask --
  • Day's Range 7.65 - 7.65
  • 52 Week Range 7.05 - 10.30
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 188.608M
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 6.83
  • EPS (TTM) 1.12
  • Earnings Date May 7, 2025 - May 12, 2025
  • Forward Dividend & Yield 0.28 (3.59%)
  • Ex-Dividend Date Sep 29, 2025
  • 1y Target Est --

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, as well as information regarding pharmaceuticals and health; and contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

www.fujipharma.jp

1,658

Full Time Employees

September 30

Fiscal Year Ends

Recent News: FUP.F

View More

Performance Overview: FUP.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

FUP.F
160.73%
Nikkei 225 (^N225)
15.33%

1-Year Return

FUP.F
65.99%
Nikkei 225 (^N225)
15.07%

3-Year Return

FUP.F
87.18%
Nikkei 225 (^N225)
21.79%

5-Year Return

FUP.F
1.91%
Nikkei 225 (^N225)
89.56%

Compare To: FUP.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FUP.F

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    188.61M

  • Enterprise Value

    354.02M

  • Trailing P/E

    6.83

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.62

  • Price/Book (mrq)

    0.63

  • Enterprise Value/Revenue

    1.18

  • Enterprise Value/EBITDA

    9.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.09%

  • Return on Assets (ttm)

    3.69%

  • Return on Equity (ttm)

    9.80%

  • Revenue (ttm)

    48.39B

  • Net Income Avi to Common (ttm)

    4.4B

  • Diluted EPS (ttm)

    1.12

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.7B

  • Total Debt/Equity (mrq)

    63.68%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: FUP.F

View More

Company Insights: FUP.F

Research Reports: FUP.F

View More

People Also Watch